Literature DB >> 2981344

Constitutive expression of Epstein-Barr virus-encoded RNAs and nuclear antigen during latency and after induction of Epstein-Barr virus replication.

R Weigel, D K Fischer, L Heston, G Miller.   

Abstract

We examined the fate of two major products of latency as Epstein-Barr virus was induced to replicate. We studied a superinducible clone of HR-1 cells in the presence and absence of induction by phorbol ester, and we analyzed the X50-7 line with and without superinfection by an HR-1 viral variant which disrupts latency. The two methods of induction yielded qualitatively similar results. After induction, there was abundant synthesis of viral transcripts, amplification of viral DNA, and the appearance of many new viral polypeptides. Nonetheless, there were no changes in the cytoplasmic abundance of Epstein-Barr virus-encoded RNAs and no alteration in the level of Epstein-Barr virus nuclear antigen mRNA or polypeptide. Thus, under conditions in which numerous other Epstein-Barr virus gene products are activated, the two major latent gene products are expressed at a constitutive level. Expression of Epstein-Barr virus-encoded RNAs and nuclear antigen must therefore be regulated in a manner completely different from expression of replicative functions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981344      PMCID: PMC255024     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Epstein-Barr virus DNA is amplified in transformed lymphocytes.

Authors:  B Sugden; M Phelps; J Domoradzki
Journal:  J Virol       Date:  1979-09       Impact factor: 5.103

2.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

3.  Transcription maps of polyoma virus-specific RNA: analysis by two-dimensional nuclease S1 gel mapping.

Authors:  J Favaloro; R Treisman; R Kamen
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

4.  Epstein-Barr virus RNA. VIII. Viral RNA in permissively infected B95-8 cells.

Authors:  M Hummel; E Kieff
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

5.  New Epstein-Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma.

Authors:  L Heston; M Rabson; N Brown; G Miller
Journal:  Nature       Date:  1982-01-14       Impact factor: 49.962

6.  Identification of an Epstein-Barr virus nuclear antigen by fluoroimmunoelectrophoresis and radioimmunoelectrophoresis.

Authors:  B C Strnad; T C Schuster; R F Hopkins; R H Neubauer; H Rabin
Journal:  J Virol       Date:  1981-06       Impact factor: 5.103

7.  Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection.

Authors:  B Thimmappaya; C Weinberger; R J Schneider; T Shenk
Journal:  Cell       Date:  1982-12       Impact factor: 41.582

8.  Major EB virus-specific cytoplasmic transcripts in a cellular clone of the HR-1 Burkitt lymphoma line during latency and after induction of viral replicative cycle by phorbol esters.

Authors:  R Weigel; G Miller
Journal:  Virology       Date:  1983-03       Impact factor: 3.616

9.  Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells.

Authors:  M Rabson; L Heston; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

10.  Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus.

Authors:  M R Lerner; N C Andrews; G Miller; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

View more
  16 in total

1.  Epstein-Barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient.

Authors:  Andi Krumbholz; Tim Sandhaus; Angela Göhlert; Albert Heim; Roland Zell; Renate Egerer; Martin Breuer; Eberhard Straube; Peter Wutzler; Andreas Sauerbrei
Journal:  Med Microbiol Immunol       Date:  2010-07-20       Impact factor: 3.402

2.  Epstein-Barr virus small RNA (EBER) genes: differential regulation during lytic viral replication.

Authors:  N Greifenegger; M Jäger; L A Kunz-Schughart; H Wolf; F Schwarzmann
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

3.  Induction of anti-EBNA-1 protein by 12-O-tetradecanoylphorbol-13-acetate treatment of human lymphoblastoid cells.

Authors:  L T Wen; A Tanaka; M Nonoyama
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

4.  Relative rates of RNA synthesis across the genome of Epstein-Barr virus are highest near oriP and oriLyt.

Authors:  S Metzenberg
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

5.  Structural analyses of EBER1 and EBER2 ribonucleoprotein particles present in Epstein-Barr virus-infected cells.

Authors:  J N Glickman; J G Howe; J A Steitz
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

6.  Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency.

Authors:  J Countryman; H Jenson; R Seibl; H Wolf; G Miller
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

7.  Latent and viral replicative transcription in vivo from the BamHI K fragment of Epstein-Barr virus DNA.

Authors:  R Weigel; G Miller
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

8.  Deletion mutants that affect expression of Epstein-Barr virus nuclear antigen in COS-1 cells after gene transfer with simian virus 40 vectors containing portions of the BamHI K fragment.

Authors:  M Polvino-Bodnar; D Shedd; G Miller
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

9.  Posttranslational processing of an Epstein-Barr virus-encoded membrane protein expressed in cells transformed by Epstein-Barr virus.

Authors:  V R Baichwal; B Sugden
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

10.  Partial elimination of Epstein-Barr virus plasmids from Burkitt's lymphoma cells by transfecting the BZLF1 gene.

Authors:  K Takada; Z Ji; S Fujiwara; N Shimizu; A Tanabe-Tochikura
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.